全球首仿地加瑞克获批上市,中国生物制药挑战专利再成功、赢得市场独占期

动脉网
Sep 16

9月15日,中国生物制药旗下正大天晴收到注射用醋酸地加瑞克的药品注册批件,用于需雄激素去势治疗的前列腺癌患者。该产品作为全球首仿,已获欧洲上市批准及美国暂时批准,并凭借专利挑战成功,赢得中国市场12个月独占期。继2023年9月获欧洲药品管理局批准、今年8月获美国食品药品监督管理局暂时批准后,该产品再获中国国家药品监督管理局批准,多国监管机构的许可,标志着公司在复杂制剂研发等方面达国际领先水平。醋酸...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10